Logo Image

Authors

Nichole Tucker
Latest Article

Novel intravesical drug delivery systems explored in bladder cancer

"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.

Joan Naidorf, DO
Latest Article

Expert advice on improving interactions with difficult patients

“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.

Nancy B. Davis, MD

Davis is an associate professor of medicine and urology and vice president for Cancer Care Network and Strategy at Vanderbilt University Medical Center, Nashville, Tennessee.

Latest Article

BCG-unresponsive NMIBC: Current evidence and options

Multiple investigational agents have been developed and are being studied.

Drogo K. Montague, MD
Austin Richards

Austin Richards is an attorney in the Columbus, Ohio, office of Reminger Co, LPA. He practices in the areas of professional liability, public entity liability and insurance litigation.

Latest Article

Malpractice Consult: What to know about closing arguments

"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.

Deborah R. Kaye, MD, MS

Kaye is an assistant professor of surgery at Duke University Medical Center, Durham, North Carolina.

Latest Article

Financial toxicity is a growing concern in urologic oncology

"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.

Rachel Passarelli, MD
Latest Article

Management of BCG-unresponsive NMIBC

"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.

Sameer Thakker, MD
Latest Article

Upper tract urothelial carcinoma: An in-depth review for urologists

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.

Russ Conroy
Latest Article

Study shows HIFU noninferior to prostatectomy for localized prostate cancer

Treating patients with localized prostate cancer with high-intensity focused ultrasound led to noninferior salvage treatment-free survival vs radical prostatectomy.

Elizabeth R. Plimack, MD, MS, FASCO
Latest Article

Biomarker may predict MIBC status following neoadjuvant chemo

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.

UCSF Health
Latest Article

Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer Care

The conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.

Daniel C. Parker, MD
Latest Article

How to perform office-based blue light cystoscopy

BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.

Jim Tudor, PCA, CPC
Latest Article

Trends in coding audits and what physicians can expect

Recent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.

Daniel D. Joyce, MD
Latest Article

Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC

Ultimately, the take-home message for practicing urologists is to apply TMT judiciously, taking into account the patient's clinical profile, personal values, and financial situation.

Lee Barrett
Latest Article

Smaller medical practices increasingly targeted for cyber attacks

Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.

Shawn Dickerson
Latest Article

Expert shares key cybersecurity fundamentals and best practices

Cybersecurity training is vital because it is mandated by HIPAA.

Vanderbilt University Medical Center
Latest Article

Phase 3 CELLEBRATE trial testing regenerative stem cell-based therapy to improve urinary control for women

The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

Jonathan Stein, PhD
Latest Article

Expert urges widespread adoption of next-generation sequencing among physicians

NGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.

David Robinson, CFP
Latest Article

UT Money Matters: Roth IRA conversions

Expert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.

Sanjay Patel, MD
Latest Article

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.

Miguel Gonzalez-Velez, MD
Latest Article

How to approach immune checkpoint inhibitor therapy in prostate cancer

Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.

Icahn School of Medicine at Mount Sinai
Latest Article

Discover the Art and Science Behind Nerve Sparing Prostate Surgery

In his latest YouTube masterclass, Dr. Ash Tewari shares his groundbreaking approach to nerve sparing prostate surgery, shedding light on the anatomy, surgical techniques, and innovations that make it possible.

Sponsored Content by Ferring Pharmaceuticals
Latest Article

Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New Frontier

Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.

Jiping Zeng, MD
Latest Article

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.

Antony Mathew, MD
Latest Article

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Tracy M. Downs, MD, FACS
Latest Article

Diversity in Urology: Progress made, but there is more work to be done

Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.

Jeff Bendix
Latest Article

What steps can physicians take to overcome barriers to health equity?

“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.

Ashling Wahner
Latest Article

177Lu-PSMA-617 prolongs rPFS in taxane-naïve mCRPC, benefit greater with prior abiraterone vs enzalutamide

Lutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.

Justin Mancini
Justin Mancini
Latest Article

The critical role of advocacy in urologic oncology

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.

Timothy A. Masterson, MD
Latest Article

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.